March 13 (Reuters) - DiaMedica Therapeutics Inc DMA.V -
* DiaMedica presents updated positive dm199 phase 1b trial identifying a superior subcutaneous delivery profile
* DiaMedica Therapeutics Inc says no treatment-limiting adverse events were reported in any dose group Source text for Eikon: ID:nCCN5yKPsd Further company coverage: DMA.V